Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Inclusion Criteria: * Moderate to severe RA despite treatment with methotrexate (MTX). * Eligible to use adalimumab according to the local label without any contraindication. * Naïve to adalimumab, and participants with prior exposure to any other biologic disease-modifying antirheumatic drugs (DMARDs) should have experienced at least five half-lives of the biologics after treatment discontinuation. * Participants for whom investigators decided to prescribe adalimumab as per local label and are initiating adalimumab at baseline. Exclusion Criteria: * Other inflammatory condition which may affect the signs on joints ultrasound (eg, gouty arthritis, or other chronic rheumatic disease besides RA). * Currently being treated with or has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days of the baseline visit. * Participants with contraindication or are not appropriate to use adalimumab according to local label or investigators' judgment.